Lilly’s Alzheimer’s Data for Donanemab

Link. “We will eventually find out if these drugs can actually help patients in the real world, or whether they do more harm than (any) good. In a more rational world, we might try finding all this out before we approve them and sell them to patients, but we’re clearly going to do it the other way.”